GYRE · Gyre Therapeutics
AI read · Neutral
The AI's read
The note does not add new information about Gyre's business. It confirms the analyst's existing view, but reports no new company results or change in that view.
H.C. Wainwright says to keep buying Gyre Therapeutics, setting a price target of $18.
Neutral
Gyre's analyst kept the Buy rating and $18 target unchanged. This repeats an existing view without new facts about Gyre's business, so it does not change the company's outlook.
Get alerts for GYRE
Follow Gyre Therapeutics (GYRE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GYREFree on the App Store and Google Play, or on the web.